Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
Ozlen H, Pichet Binette A, Köbe T, Meyer PF, Gonneaud J, St-Onge F, Provost K, Soucy JP, Rosa-Neto P, Breitner J, Poirier J, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative, the Harvard Aging Brain Study, the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease Research Group. Ozlen H, et al. Among authors: gonneaud j. JAMA Neurol. 2022 Oct 1;79(10):1025-1035. doi: 10.1001/jamaneurol.2022.2442. JAMA Neurol. 2022. PMID: 35994280 Free PMC article.
Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Villeneuve S, et al. Among authors: gonneaud j. JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135. JAMA Neurol. 2018. PMID: 29482212 Free PMC article.
Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use.
Köbe T, Gonneaud J, Pichet Binette A, Meyer PF, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Köbe T, et al. Among authors: gonneaud j. JAMA Netw Open. 2020 Feb 5;3(2):e1920780. doi: 10.1001/jamanetworkopen.2019.20780. JAMA Netw Open. 2020. PMID: 32031648 Free article.
Morphometric network differences in ageing versus Alzheimer's disease dementia.
Pichet Binette A, Gonneaud J, Vogel JW, La Joie R, Rosa-Neto P, Collins DL, Poirier J, Breitner JCS, Villeneuve S, Vachon-Presseau E; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group. Pichet Binette A, et al. Among authors: gonneaud j. Brain. 2020 Feb 1;143(2):635-649. doi: 10.1093/brain/awz414. Brain. 2020. PMID: 32040564 Free PMC article.
Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease.
Pichet Binette A, Vachon-Presseau É, Morris J, Bateman R, Benzinger T, Collins DL, Poirier J, Breitner JCS, Villeneuve S; Dominantly Inherited Alzheimer Network (DIAN); PREVENT-AD Research Group. Pichet Binette A, et al. Biol Psychiatry. 2021 Apr 15;89(8):776-785. doi: 10.1016/j.biopsych.2020.01.023. Epub 2020 Feb 6. Biol Psychiatry. 2021. PMID: 32228870 Free PMC article.
69 results